| AKR1C3 as a target in castrate resistant prostate cancer AO Adeniji, M Chen, TM Penning The Journal of steroid biochemistry and molecular biology 137, 136-149, 2013 | 146 | 2013 |
| Development of Potent and Selective Inhibitors of Aldo–Keto Reductase 1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase) Based on N-Phenyl-Aminobenzoates … AO Adeniji, BM Twenter, MC Byrns, Y Jin, M Chen, JD Winkler, ... Journal of medicinal chemistry 55 (5), 2311-2323, 2012 | 116 | 2012 |
| Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant … AJ Liedtke, AO Adeniji, M Chen, MC Byrns, Y Jin, DW Christianson, ... Journal of medicinal chemistry 56 (6), 2429-2446, 2013 | 105 | 2013 |
| Discovery of substituted 3-(phenylamino) benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) AO Adeniji, BM Twenter, MC Byrns, Y Jin, JD Winkler, TM Penning Bioorganic & medicinal chemistry letters 21 (5), 1464-1468, 2011 | 59 | 2011 |
| Crystal structures of AKR1C3 containing an N-(aryl) amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for … M Chen, AO Adeniji, BM Twenter, JD Winkler, DW Christianson, ... Bioorganic & medicinal chemistry letters 22 (10), 3492-3497, 2012 | 55 | 2012 |
| Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor A Adeniji, MJ Uddin, T Zang, D Tamae, P Wangtrakuldee, LJ Marnett, ... Journal of medicinal chemistry 59 (16), 7431-7444, 2016 | 41 | 2016 |
| Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library P Brožič, S Turk, AO Adeniji, J Konc, D Janežič, TM Penning, ... Journal of medicinal chemistry 55 (17), 7417-7424, 2012 | 27 | 2012 |
| A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics P Wangtrakuldee, AO Adeniji, T Zang, L Duan, B Khatri, BM Twenter, ... The Journal of steroid biochemistry and molecular biology 192, 105283, 2019 | 20 | 2019 |
| N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo–keto reductase AKR1C3 M Sinreih, I Sosič, N Beranič, S Turk, AO Adeniji, TM Penning, TL Rižner, ... Bioorganic & medicinal chemistry letters 22 (18), 5948-5951, 2012 | 20 | 2012 |
| Amyloid β hypothesis in the development of therapeutic agents for Alzheimer’s disease AO Adeniji, PW Adams, VV Mody Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders …, 2017 | 13 | 2017 |
| Colorimetric assay of naproxen tablets by derivatization using 4-carboxyl-2, 6-dinitrobenzene diazonium ion SO Idowu, OA Adegoke, AO Adeniji, AA Olaniyi East and Central African Journal of pharmaceutical sciences 12 (1), 2009 | 11 | 2009 |
| Syntheses and In-Vitro Evaluation of Novel Adamantane Based γ-Secretase Inhibitors A O Adeniji, R M Wells, A Adejare Current medicinal chemistry 19 (15), 2458-2471, 2012 | 8 | 2012 |
| Indomethacin analogs for the treatment of castrate-resistant prostate cancer LJ Marnett, AJ Liedtke, TM Penning, AO Adeniji, MC Byrns US Patent 9,346,803, 2016 | 5 | 2016 |
| Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof TM Penning, AO Adeniji, MC Burns, J Winkler, B Twenter US Patent 9,271,961, 2016 | 3 | 2016 |
| Indomethacin analogs for the treatment of castrate-resistant prostate cancer LJ Marnett, AJ Liedtke, TM Penning, AO Adeniji, MC Byrns US Patent 10,398,678, 2019 | 2 | 2019 |
| Crystal structures of human 17β-hydroxysteroid dehydrogenase Type 5 (AKR1C3) in complex with N-phenylanthranilic acid and indomethacin-based selective inhibitors M Chen, AO Adeniji, BM Twenter, AJ Liedtke, JD Winkler, LJ Marnett, ... Endocrine Reviews 33 (03_MeetingAbstracts), SAT-536, 2012 | 2 | 2012 |
| Development of potent and selective indomethacin analogs for the inhibition of AKR1C3 in castrate-resistant prostate cancer AO Adeniji, A Liedtke, MC Byrns, Y Jin, LJ Marnett, TM Penning Endocr. Rev 33, 2012 | 2 | 2012 |
| Indomethacin analogs for the treatment of castrate-resistant prostate cancer LJ Marnett, AJ Liedtke, TM Penning, AO Adeniji, MC Byrns US Patent 11,738,004, 2023 | 1 | 2023 |
| Indomethacin analogs for the treatment of castrate-resistant prostate cancer LJ Marnett, AJ Liedtke, TM Penning, AO Adeniji, MC Byrns US Patent App. 16/530,907, 2019 | 1 | 2019 |
| Structure activity relationship (SAR) studies of a novel γ-secretase inhibitor A Adeniji University of the Sciences in Philadelphia, 2010 | 1 | 2010 |
